Century Therapeutics, Inc. (IPSC)
D
Pipeline Grade
Financial Position (from SEC Filings)
$53.8M
Cash & Equivalents
$25.3M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$406M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05768269 | A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | OTHER | Recruiting | 375 |
| NCT06255028 | A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases | PHASE1 | Active Not Recruiting | 6 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-08 | 8-K | Century Therapeutics, Inc. (IPSC) (CIK 0001850119) - EXHIBIT 99.1 | EDGAR |